Company Dossier · Health Care
Revvity
- S&P 500
- Russell 1000
What Revvity is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to July 5, 2026: $2.91 billion, up 3.9% from a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to July 5, 2026: $0.56 billion, up 12% from a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to July 5, 2026: $0.07 billion, down 12% from a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to December 28, 2025: $0.82 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 4, 2026): sentiment 0.80 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
- Guidance in the last 90 days: 3 outlook figures raised, 0 lowered, 0 held.Guidance Ledger (8-K results releases)
- Latest annual report (filed February 24, 2026): 1 risk factor added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q3 2026: $1.3 million on the open market.SEC Form 4
- 545 institutional managers reported a position at June 30, 2026 (+42 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 11 (10 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Revvity is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Retrenching · Confident
Expanding ↔ Retrenching
Retrenching
- Capital spending16th pct
- Debt raised—
- Buybacks vs capex26th pct
- Hiring filings36th pct
- Deals and private raises45th pct
- Patent publications81st pct
Confident ↔ Hedging
Confident
- Call sentiment94th pct
- Call confidence69th pct
- Guidance changes73rd pct
- Risk factors added42nd pct
- Insider open-market trades44th pct
- + Call sentiment
- + Guidance changes
- + Call confidence
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver5th pct
- Stress filings48th pct
Credit
How these are built →Revvity's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$3.2B
- Due within a year $0.6B
- Longer term $2.6B
- Default point $1.9B (short + ½ long)
Finance leases included · Jul 5, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 15, 2026LobbyingLobbying report (REVVITY, INC.)third_quarter 2026 · $0.0 million
- Sep 29, 2026Patent
- Sep 15, 2026Patent
- Jul 28, 2026Patent
- Jul 14, 2026Patent
- Jul 13, 2026LobbyingLobbying report (REVVITY, INC.)second_quarter 2026 · $0.0 million
- Jul 7, 2026Patent
- May 1, 20268-KShareholder vote resultsItem 5.07
- Apr 23, 2026LobbyingLobbying report (REVVITY, INC.)first_quarter 2026 · $0.0 million
- Feb 24, 202610-KAnnual report (10-K)1 risk factors added, 0 removed
- Jan 9, 2026LobbyingLobbying report (REVVITY, INC.)fourth_quarter 2025 · $0.0 million
- Dec 23, 2025Trademark
- Oct 24, 20258-KDirector or officer changeItem 5.02
- Oct 2, 2025LobbyingLobbying report (REVVITY, INC.)third_quarter 2025 · $0.0 million
- May 5, 2025Trademark
- Apr 25, 20258-KShareholder vote resultsItem 5.07
- Apr 24, 2025LobbyingLobbying report (REVVITY, INC.)second_quarter 2025 · $0.0 million
- Apr 24, 2025LobbyingLobbying report (REVVITY, INC.)first_quarter 2021
- Apr 7, 2025LobbyingLobbying report (REVVITY, INC.)first_quarter 2025 · $0.1 million
- Feb 25, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Jan 7, 20258-KMaterial agreement signedItem 1.01
- Jan 7, 20258-KMaterial agreement terminatedItem 1.02
- Feb 27, 202410-KAnnual report (10-K)1 risk factors added, 2 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Insulet Corporation PODD | $3.0B | $0.3B | Jun 30, 2026 |
| Globus Medical GMED | $3.1B | $0.8B | Jun 30, 2026 |
| Bruker BRKR | $3.5B | $0.1B | Jun 30, 2026 |
| Teleflex TFX | $2.3B | $0.2B | Jun 30, 2026 |
| Idexx Laboratories IDXX | $4.5B | $1.3B | Jun 30, 2026 |
| Dexcom DXCM | $5.0B | $1.4B | Jun 30, 2026 |
| Penumbra, Inc. PEN | $1.5B | $0.2B | Jun 30, 2026 |
| ResMed| RMD | $5.7B | $1.6B | Jun 30, 2026 |